ArticleScientific reports2025
PGRP-S promotes hepatocellular carcinoma progression via MAPK/ERK pathway by interaction with TTC1.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Retraction · 2026-05-12Contamination of Cell Lines/Tissues · Duplication of/in Image · Unreliable Results and/or Conclusions · · See also: https://pubpeer.com/publications/ED7C3AA1ED404DC3FE173AE9D7C853
- Retracted
Authors and funding
8 authors.
Funding
Abstract
Abnormal expression of PGRP-S plays an important role in the development and progression of hepatocellular carcinoma (HCC), although the mechanism has remained elusive. In this study, we aimed to investigate the biological function and potential mechanism of PGRP-S in HCC. We found that PGRP-S was upregulated in HCC tissues compared to adjacent tissues. The increased expression of PGRP-S correlated with the differentiation and lymph node metastasis of HCC. PGRP-S obviously promoted HCC cell proliferation, migration and invasion in vitro. In vivo nude mouse models showed that PGRP-S enhanced tumor growth and pulmonary metastasis. Mechanistically, PGRP-S interacted with TTC1 and activated MAPK/ERK pathway, leading to HCC cell proliferation, migration and invasion. Therfore, our conclusion is PGRP-S promotes HCC cell proliferation, migration and invasion by activating MAPK/ERK pathway, which provides a new potential strategy for HCC treatment by targeting PGRP-S-TTC1 axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.